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SUMMARY
Nakajo-Nishimura syndrome (NNS) is an immunoproteasome-associated autoinflammatory disorder caused by amutation of the PSMB8
gene. Although dysfunction of the immunoproteasome causes various cellular stresses attributed to the overproduction of inflammatory
cytokines and chemokines in NNS, the underlying mechanisms of the autoinflammation are still largely unknown. To investigate and
understand the mechanisms and signal pathways in NNS, we established a panel of isogenic pluripotent stem cell (PSC) lines with
PSMB8 mutation. Activity of the immunoproteasome in PSMB8-mutant PSC-derived myeloid cell lines (MT-MLs) was reduced even
without stimulation compared with non-mutant-MLs. In addition, MT-MLs showed an overproduction of inflammatory cytokines
and chemokines, with elevated reactive oxygen species (ROS) and phosphorylated p38MAPK levels. Treatment with p38MAPK inhibitor
and antioxidants decreased the abnormal production of cytokines and chemokines. The current PSCmodel revealed a specific ROS-medi-
ated inflammatory pathway, providing a platform for the discovery of alternative therapeutic options for NNS and related immunopro-
teasome disorders.
INTRODUCTION
Autoinflammatory disorders caused by the dysfunction of
proteasomes have been collectively designated as protea-
some-associated autoinflammatory syndromes (PRAASs)
(Almeida de Jesus and Goldbach-Mansky, 2013; Brehm
et al., 2015; McDermott et al., 2015). PRAASs were origi-
nally defined as mutations in the immunoproteasome
component of proteasome subunit beta 8 (PSMB8) gene,
but have been since expanded to include the dysregula-
tion of both the constitutive proteasome and the immu-
noproteasome (Brehm et al., 2015; McDermott et al.,
2015). PRAASs include Nakajo-Nishimura syndrome
(NNS; also known as autoinflammation, lipodystrophy,
and dermatosis syndrome) (Arima et al., 2011), Japanese
autoinflammatory syndrome with lipodystrophy (Kita-
mura et al., 2011), joint contractures, muscular atrophy,
microcytic anemia, panniculitis-associated lipodystrophy
syndrome (Garg et al., 2010), and chronic atypical neutro-
philic dermatosis with lipodystrophy and elevated tem-
perature (CANDLE) syndrome (Brehm et al., 2016; Liu
et al., 2012). NNS is an autosomal recessive disorder
caused by a homozygous mutation in the PSMB8 gene
(Arima et al., 2011; Kitamura et al., 2011). Patients with
NNS show pernio-like skin rashes from infancy and grad-
ually develop partial lipodystrophy mainly in the face and
upper extremities, as well as show characteristically long
clubbed fingers with contracture of the interphalangeal
joints. Patients also suffer from remittent fever and
nodular erythema-like skin eruptions (Arima et al., 2011;
Kunimoto et al., 2013). Although the administration of
systemic corticosteroids is partially effective, particularly
against skin lesions, the prognosis remains relatively
poor since this therapy is ineffective on lipodystrophy.
Since there is currently no curative therapy for NNS and
most patients die as a result of respiratory or cardiac fail-
ure (Arima et al., 2011; Kanazawa, 2012), therapeutic ad-
vances for NNS are desired.
Proteasomes are highly efficient proteolytic machinery
for degrading damaged or unnecessary proteins (van
Deventer and Neefjes, 2010). PSMB8 gene encodes b5i pro-
tein, which is a subunit of a specialized type of proteasome
named immunoproteasome. The catalytic component of
the constitutive proteasome consists of three protease sub-
units: chymotrypsin-like enzyme b5, trypsin-like enzyme
b2, and caspase-like enzyme b1 (Murata et al., 2009; Reis
et al., 2011). These three subunits correspond to immuno-
proteasome subunits b5i, b2i, and b1i, respectively. The im-
munoproteasome is constitutively expressed in hemato-
poietic cells (McCarthy and Weinberg, 2015; Roccaro
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et al., 2010). In addition, in immune cells, immunoprotea-
some subunits are upregulated and replace their corre-
sponding constitutive proteasome subunits upon stimula-
tion with proinflammatory cytokines such as interferon
gamma (IFN-g) and tumor necrosis factor alpha (TNF-a)
(Kimura et al., 2015; McCarthy and Weinberg, 2015). The
immunoproteasome has a role in processing endogenous
peptides that are presented on major histocompatibility
complex I molecules (Groettrup et al., 2010; Reis et al.,
2011).
Almost all Japanese NNS patients share the same
homozygous point mutation, c.602G > T, which causes
substitution of glycine 201 to valine (Arima et al.,
2011; Kunimoto et al., 2013). NNS-associated PSMB8
mutations cause impaired assembly of the immunopro-
teasome, resulting in a reduction of immunoproteasome
activity in immune cells. This impaired immunoprotea-
some activity causes an accumulation of ubiquitinated
and oxidized proteins (Arima et al., 2011) and is attrib-
uted to the elevation of the serum concentration of
several proinflammatory cytokines and chemokines,
such as IL-6, IP-10 and MCP-1 in NNS patients (Arima
et al., 2011). Although involvement of the p38
mitogen-activated protein kinase (p38 MAPK) pathway
in the upregulation of proinflammatory cytokines was
implicated in NNS patients (Arima et al., 2011), the pre-
cise pathway harnessing immunoproteasome dysfunc-
tion to the overproduction of proinflammatory cytokines
remains unclear.
Among PRAASs, CANDLE syndrome has recently been
recognized as an IFN-driven disease and shows a promi-
nent IFN signature (Liu et al., 2012). A JAK inhibitor,
baricitinib, is currently undergoing clinical trial (clinical-
trials.gov: NCT01724580) (Jabbari et al., 2015). On the
other hand, although NNS and CANDLE share the same
responsible gene, whether NNS symptoms are also driven
by the IFN pathway has not been clarified. To investigate
the detailed mechanism and signal pathways in NNS as
well as to seek potential therapeutic candidates, in the
current study we focused on establishing a pluripotent
stem cell (PSC) model using NNS patient-derived induced
pluripotent stem cells (iPSCs) and isogenic controls.
We then recapitulated the in vitro phenotypes of
NNS by differentiating the iPSCs into myeloid cell lines
(PSC-MLs) (Haruta et al., 2013). NNS-PSC-MLs showed
reduced proteasome activity and increased production of
IL-6, MCP-1, and IP-10. Since these phenotypes corre-
sponded to those of patient-derived peripheral blood
monocytes, we concluded that our in vitro NNS-iPSC
model successfully recapitulated the patient condition.
We then validated several compounds for ameliorating
the proinflammatory responses of NNS. Our isogenic
PSC models are useful for elucidating the pathophysi-
ology of NNS and also for providing a platform for
high-throughput drug screening.
RESULTS
Establishment of NNS-iPSCs and the Generation of
Isogenic PSC Panels
Dermal fibroblasts were obtained from three NNS pa-
tients who shared the same homozygous mutation of
PSMB8 gene (Table S1, p.G201V [c.602G > T]) (Arima
et al., 2011). The clinical features of all three NNS cases
are summarized in Table S1. These fibroblasts were re-
programmed by introducing retroviral vectors encoding
OCT3/4, SOX2, KLF4, and cMYC (Takahashi et al.,
2007). Two iPSC clones from each NNS patient were
randomly selected and propagated. All iPSC clones
showed a typical characteristic human embryonic stem
cell (ESC)-like morphology (Figure S1A) and expressed
PSC-specific markers NANOG and SSEA4 (Figure S1A).
The expression of residual transgenes was rarely detected
(Figure S1B). All iPSC clones also maintained a normal
karyotype (Figure S1C), and their pluripotency was
confirmed by the formation of teratomas composed of
all three germ layers (Figure S1D). The chymotrypsin-
like activity of undifferentiated patient-derived iPSCs
was comparable to that of the control PSCs even after
IFN-g and TNF-a stimulation (Figure S1E). Since all 6
NNS-iPSC clones from three individuals exhibited similar
characteristics, including hematopoietic differentiation
efficiency (Table S2), we selected a representative iPSC
clone from patient 1 (NNS1-1, hereafter referred to as
NNS1-1 [MT]) and used it for the subsequent analysis.
To precisely evaluate the mutant-specific phenotype, we
attempted to generate isogenic iPSCs by correcting the
corresponding PSMB8 mutation using the CRISPR-Cas9
(D10A) nickase-mediated double-nicking system (Ran
et al., 2013; Zhou et al., 2014) (Figures 1A and S2A).
We tested two single-guide RNA (sgRNA) sequences for
each breakpoint and found that the sgRNA pair sg1-2/
sg2-1 showed the highest rate of homozygous recombi-
nation-mediated gene replacement: out of three puromy-
cin-resistant clones analyzed, one clone was heterozy-
gously targeted and two clones were homozygously
targeted (Figure S2B). Hereafter, we selected the homozy-
gously targeted clone, referred to as NNS1-1 (WT), which
was validated by a genomic PCR (Figure S2C). The loxP-
flanked puromycin selection cassette was removed from
each targeted iPSC clone by transient transfection with
a vector expressing Cre recombinase. We also checked
the T-to-G homozygous correction on exon 5 of the
PSMB8 gene by Sanger sequencing (Figure S2D). In a
similar way, we generated homozygous PSMB8-G201V
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knockin PSCs from a control human ESC line, KhES-1
(referred to as KhES-1 [WT] for control KhES-1, and
KhES-1 [MT] for PSMB8-mutated KhES-1; Figures 1A
and S2E–S2G). It was previously shown that the selective
inhibition of two immunoproteasome subunits (b1i and
b5i) results in the downregulation of several pluripo-
tency markers in human ESCs (Atkinson et al., 2012),
indicating immunoproteasome subunits may affect the
maintenance of pluripotency. However, in our hands,
there was no difference in the expression of PSC-associ-
ated markers and in vivo pluripotency between MT- and
WT-clones (Figures S1A, S1B, and S1D). The efficiency
of reprogramming and the efficiency of genome editing
were also comparable between MT- and WT-clones (Table
S2 and Figures S2C and S2F). Therefore, at least in this
study, the disease-associated mutant PSMB8 seemed not
to affect the biological features of undifferentiated
PSCs. Overall, we successfully established isogenic dis-
ease-control pairs using patient-derived iPSCs and
genome-editing technology, which enabled us to pre-
cisely evaluate the effects of the disease-causing PSMB8
mutation in PSC-derived differentiated cells.
Impairment of Immunoproteasome Activity in
PSMB8-Mutant PSC-Derived Monocytic Cell Lines
Previous histopathological examination of the inflamma-
tory sites in NNS patients has shown the infiltration of
CD68+, myeloperoxidase-positive monocytic cells and
CD3+ T cells (Kunimoto et al., 2013). Since macrophages
are the primary source of inflammatory cytokines and pre-
dominantly express the immunoproteasome (Ebstein
et al., 2012; McCarthy and Weinberg, 2015), we focused
on the in vitro phenotypes of differentiated monocytic
cells from PSCs. CD14+ monocytes were differentiated
from PSCs according to a previously described protocol
with approximately 90% purity (Figures 1B and S3A)
(Yanagimachi et al., 2013). To stably obtain an unlimited
number of differentiated cells, PSC-derived monocytes
were immortalized by transducing lentivirus vectors
that encoded MDM2, BMI1, and cMYC (Haruta et al.,
2013; Kawasaki et al., 2017) (Figure 1B). The established
PSC-derived monocytic cell lines (PSC-MLs) maintained
the expression of monocyte markers CD14 and CD33
(Figure S3A) and showed a morphology that was compat-
ible with monocytic cells (Figure S3B). We measured the
proteasome activity, especially the chymotrypsin-like ac-
tivity in PSC-MLs, using a luciferase-based proteasome
assay. When the immunoproteasome assembly was
induced by IFN-g and TNF-a, we observed an upregula-
tion of chymotrypsin-like activity in wild-type PSC-MLs
(WT-MLs) (Figure 1C). However, this upregulation was
not observed in mutant PSC-MLs (MT-MLs) (Figure 1C).
When the activity levels of b5 and b5i were separately
evaluated in the IFN-g- and TNF-a-treated PSC-MLs, we
found the activity of constitutive subunit b5 was not
affected in any PSC-ML (Figure 1D). In contrast, although
treatment of WT-MLs with IFN-g and TNF-a elevated the
immunoproteasome subunit b5i activity, the activity was
significantly lower in NNS1-1-(MT)-MLs, and there was
no elevation in b5i activity in KhES-1-(MT)-MLs (Fig-
ure 1E). Notably, the baseline activity of b5i was already
decreased in both MT-MLs (Figure 1E), possibly due to
the constitutive expression of immunoproteasome pro-
teins in hematopoietic cells (McCarthy and Weinberg,
2015). The decreased chymotrypsin-like activity in
IFN-g- and TNF-a-treated cells was confirmed in primary
monocytes from NNS patients (Figure S3C). Since all pro-
teasome b subunits except b3 and b4 are translated as pre-
cursors containing N-terminal pro-regions (Yun et al.,
2016), we next evaluated the maturation of b5i protein
in PSC-MLs. When untreated, b5i was constitutively ex-
pressed in both WT-MLs and MT-MLs, but its maturation
was relatively impaired in MT-MLs (Figures 1F and 1G).
Other proteasome subunits were also expressed in PSC-
MLs (Figure S3D). When treated with IFN-g and TNF-a,
the maturation of b2i and b1i was also impaired in
MT-MLs (Figure S3D). MT-MLs showed an accumulation
of ubiquitinated proteins in comparison with WT-MLs
not only with IFN-g and TNF-a stimulation, but also in
an untreated state (Figure 1H). These data support the
physiological dysfunction of the immunoproteasome ma-
chinery in PSMB8-mutant PSC-derived monocytic cells.
Figure 1. The Establishment of an Isogenic PSC Panel for NNS Study
(A) Study design.
(B) The protocol for monocytic differentiation and the establishment of PSC-MLs.
(C–E) The chymotrypsin-like activity of PSC-MLs was measured by a luciferase-based assay. The chymotrypsin-like activity was normalized
according to the number of cells. The chymotrypsin-like proteolytic activities of constitutive proteasome (D, b5 subunit) and im-
munoproteasome (E, b5i subunit) in PSC-MLs. Background fluorescence or luminescence was subtracted from each value. Bars indicate the
means ±SD (n = 3). Asterisks indicate statistically significant differences by Student’s t test: *p < 0.05; **p < 0.01.
(F) Western blotting of immunoproteasome subunits b5i and a6.
(G) The quantity of mature b5i in (F) was normalized by the expression of immature b5i.
(H) Western blotting of ubiquitinated proteins.
In (C)–(H), the cells were treated with IFN-g (100 ng/mL) and TNF-a (100 ng/mL) for 20 hr.
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Immunoproteasome Deficiency Causes an Aberrant
Proinflammatory Response in MT-MLs
We next investigated the cytokine and chemokine secre-
tion profiles in PSC-MLs. IFN-a and IFN-b production was
not observed in either WT-MLs or MT-MLs following
IFN-g and TNF-a or LPS stimulation (data not shown).
IL-10 and IL-1b were also not detected in either WT-MLs
or MT-MLs following IFN-g and TNF-a stimulation (data
not shown). However, IFN-g and TNF-a stimulation signif-
icantly increased the secretion of proinflammatory cyto-
kine IL-6 and proinflammatory chemokine MCP-1 in
MT-MLs in comparison with the isogenic WT-ML counter-
parts (Figure 2A). Since an elevated IFN signature has been
observed in other PSMB8-assocated autoinflammatory dis-
eases (Brehm et al., 2016; Liu et al., 2012), we next
measured the secretion of an IFN-responsive chemokine,
IP-10. The secretion of IP-10 in MT-MLs and WT-MLs did
not differ to a statistically significant extent following
IFN-g and TNF-a stimulation (Figure 2B). However, upon
stimulation with only type II (IFN-g) or type I (IFN-a)
IFN, MT-MLs secreted a significantly higher amount of IP-
10 in comparison with WT-MLs (Figure 2C). Both type I
and type II IFNs induced the robust secretion of IP-10. We
therefore focused on the effect of type II IFN in the subse-
quent analysis. The increased production of IL-6 and
IP-10 was confirmed with primary monocytes obtained
from NNS patients (Figure S3E). Since the excessive secre-
tion of these cytokine and chemokines fromMT-MLs corre-
sponds to previous serum cytokine levels in NNS patients
(Arima et al., 2011), we considered our PSC-based in vitro
model as having successfully recapitulated the cellular phe-
notypes of monocytic cells with an NNS-associated PSMB8
mutation.
Untreated and Stimulated MT-MLs Show Distinct
Proinflammatory Transcriptional Profiles
To reveal the specific inflammatory signatures of MT-MLs,
we next performed RNA-sequencing (RNA-seq) analysis of
the PSC-MLs. Most of the proteasome subunits, including
b5i, b2i, and b1i, were upregulated upon IFN-g and TNF-a
treatment in both MT- and WT-MLs (Figure S3F). On the
other hand, the expression of IFN-a or IFN-b genes was
not detected even under the stimulated condition (Fig-
ure S3G). A principal component analysis from the
normalized gene counts showed that the samples were
clearly grouped according to the genotypes of PSMB8
and stimulation (Figure 2D). MT-MLs and WT-MLs were
distinguished even when untreated, indicating that
PSMB8-mutant cells were in a ‘‘primed’’ state before stim-
ulation. In order to extract differences in the regulation
of the pathways in MT-MLs and WT-MLs, we performed
a gene set enrichment analysis (Subramanian et al.,
2005). Upon IFN-g and TNF-a treatment of the MT-MLs,
several inflammatory pathways, in particular interferon-
associated pathways including ‘‘INTERFERON_GAMMA_
RESPONSE," ‘‘INTERFERON_ALPHA_RESPONSE,’’ and
‘‘TNF-A_SIGNALING_VIA_NF-kB,’’ were significantly en-
riched (false discovery rate < 0.25; p < 0.01) in comparison
with WT-MLs (Figure 2E). Especially, genes associated
with type I and type II IFN responses were upregulated
in MT-MLs (Figures 2F and 2G). These results suggest
that the aberrant expression of genes, cytokines, and che-
mokines is associated with the PSMB8 mutation even in
an untreated state as well as in response to IFN-g and
TNF-a stimulation.
Since the NNS-associated PSMB8 mutation is consid-
ered hypo-functional, we next wondered whether phar-
macological inhibition of b5i could mimic the in vitro
phenotypes of NNS. For this experiment, we pretreated
PSC-MLs with a selective b5i inhibitor, ONX-0914 (Mu-
chamuel et al., 2009), and evaluated the cytokine produc-
tion. ONX-0914 decreased the chymotrypsin-like activity
of WT-MLs stimulated with IFN-g and TNF-a (Figure S4A).
While a low dose of ONX-0914 increased the secretion of
IL-6 and MCP-1, a high dose showed an anti-correlative
inhibitory effect on the secretion of IL-6 and MCP-1,
even though the chymotrypsin-like activity was inhibited
(Figures S4B and S4C). On the other hand, the secretion
of IP-10 from WT-MLs was reduced by pretreatment
with ONX-0914 (Figures S4B and S4C). Since PSMB8-
mutant MLs showed a consistent increase in the secretion
of these cytokines, these results are inconsistent with
Figure 2. Functional Properties of PSC-MLs
(A and B) The amount of IL-6, MCP-1, and IP-10 secreted from PSC-MLs in response to treatment with IFN-g (100 ng/mL) and TNF-a
(100 ng/mL) for 20 hr. Bars indicate the means ±SD (n = 3). Asterisks indicate statistically significant differences by Student’s t test:
*p < 0.05; **p < 0.01.
(C) The amount of IP-10 secreted in response to treatment with type II (IFN-g, 100 ng/mL) or type I IFN (IFN-a) for 20 hr. Bars indicate the
means ±SD (n = 3).
(D) A principal component analysis based on normalized RNA-seq data. Each symbol indicates each clone and treatment.
(E) Gene set enrichment analysis. Gene sets that were significantly (false discovery rate <0.25) enriched in MT-MLs treated with IFN-g and
TNF-a are shown.
(F and G) Heat maps of genes belonging to gene ontologies associated with type I (F) and type II (G) IFN responses. Columns are mean-
centered with relative abundance represented by color (blue, lower abundance; red, higher abundance).
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findings in NNS patients. The reason for this discrepancy
is currently unknown, but we suppose it is associated
with specific mutant PSMB8 functions. Nevertheless,
these data underscore the significance of mutant models
instead of pharmacological models for the study of the
NNS pathophysiology.
Effects of a Series of Anti-inflammatory Compounds
on PSC-MLs Reveal the Specific Inflammatory
Pathway in NNS
Because the cytokine assays and RNA-seq data indicated
the activation of inflammatory pathways in MT-ML lines,
we evaluated the effects of several anti-inflammatory
compounds on IFN-g- and TNF-a-treated PSC-MLs. First,
PSC-MLs were pretreated with an anti-inflammatory
corticosteroid, dexamethasone, which inhibits the activa-
tion of the NF-kB and MAPK pathways (Bhattacharyya
et al., 2010). Dexamethasone slightly reduced the secre-
tion of IL-6 and MCP-1, but not in all PSC-MLs, while
the level of IP-10 was not affected (Figure 3A). Next, we
attempted to inhibit downstream of the IFN pathway
by using a pan-JAK inhibitor, tetracyclic pyridone 6 (P6)
(Lucet et al., 2006; Pedranzini et al., 2006), a potent,
cell-permeable, and ATP competitive inhibitor of JAK1,
JAK2, JAK3, and Tyk2. P6 inhibited the secretion of
IP-10, IL-6, and MCP-1 in a dose-dependent manner
(Figure 3B). We also evaluated the effect of another JAK
inhibitor, baricitinib, on IFN-g- and TNF-a-treated
PSC-MLs, because it is an approved drug and a clinical
trial of baricitinib for CANDLE syndrome is ongoing (Jab-
bari et al., 2015). As expected, baricitinib inhibited the
secretion of IP-10, IL-6, and MCP-1 in a dose-dependent
manner (Figure S5).
Since the enhanced phosphorylation of p38 MAPK
in inflamed tissue was observed in NNS patients (Arima
et al., 2011), we wondered whether the enhanced
p38 MAPK pathway was responsible for the proinflam-
matory response in MT-MLs. We therefore evaluated
the effect of SB202190, a p38 MAPK inhibitor (Manthey
et al., 1998). SB202190 inhibited the secretion of IL-6,
IP-10, and MCP-1 in a dose-dependent manner (Fig-
ure 3C). Intriguingly, SB202190 and P6 showed similar
potency at inhibiting the secretion of IP-10 and MCP-1
even under stimulation by IFN-g alone (Figures 3D
and 3E), indicating the possibility of pathological cross-
talk between the IFN pathway and the p38 MAPK
pathway in MT-MLs.
Excessive Production of Reactive Oxygen Species in
MT-MLs Contributes to Proinflammatory Responses
through Activation of the p38 MAPK and IFN-g
Pathways
Impaired immunoproteasome activity can cause an
abnormal accumulation of proteins and might therefore
cause various stresses in cells. Proteasome dysfunction
due to the use of the chemical inhibitor bortezomib causes
damage to the mitochondria, leading the cells to increase
their production of reactive oxygen species (ROS), which
results in cytosolic oxidation (Maharjan et al., 2014).
Oxidative stress can cause an increased production of in-
flammatory cytokines and chemokines (Naik and Dixit,
2011). Indeed, the intracellular production of ROS is
increased in MT-MLs regardless of IFN-g and TNF-a stimu-
lation (Figures 4A and 4B). We therefore examined the ef-
fects of antioxidants on the production of cytokines and
chemokines. The pretreatment of PSC-MLs with gluta-
thione-SH (GSH) before IFN-g and TNF-a stimulation
reduced the secretion of IL-6 and MCP-1 (Figure 4C). In
the presence of another antioxidant, N-acetyl-cysteine
(NAC), the secretion of IL-6, MCP-1, and IP-10 was also
significantly reduced (Figure 4D). Of note, higher concen-
trations of GSH or NAC markedly or completely inhibited
the secretion of these cytokines and chemokines (Figures
4C and 4D). Interestingly, GSH and NAC also potently in-
hibited the secretion of IP-10 andMCP-1, even under stim-
ulation with IFN-g alone, indicating the contribution of
ROS in the IFN-g pathway inNNS (Figures 4E and 4F). Over-
all, these data indicate the important role that excessive
ROS production plays in the proinflammatory response
of NNS patient-derived monocytic cells. In previous re-
ports, intracellular ROSwas found to be an essential second
messenger in various signal cascades (Yang et al., 2013).
Proteasome dysfunction-mediated ROS can enhance the
activation of the p38 MAPK pathway (Maharjan et al.,
2014; Son et al., 2011), and the JAK/STAT pathway re-
sponds to intracellular ROS upon stimulation (Simon
et al., 1998). Indeed, the phosphorylation of p38 MAPK
in NNS patient lymphocytes was greater than that in
healthy controls (Arima et al., 2011; Kitamura et al.,
2011). Higher levels of phosphorylated STAT1 (pY701)
and p38 MAPK (pT180/Y182) were observed in MT-MLs
as well, even in an untreated state (Figure 5A), as too was
the constitutive expression of p38 MAPK in MT-MLs (Fig-
ure 5A). The increased phosphorylation of STAT1 in un-
treated MT-MLs was ameliorated by NAC treatment
Figure 3. Effects of Anti-inflammatory Compounds on IFN-g- and TNF-a-Treated PSC-MLs
(A–E) The amount of IL-6, MCP-1, and IP-10 secreted from PSC-MLs. Cells were pretreated 3 hr with the indicated compounds and sub-
sequently treated with IFN-g and TNF-a (A–C) or IFN-g only (D and E) for 20 hr. Bars indicate the means ±SD (n = 3). Asterisks indicate
statistically significant differences by Student’s t test: *p < 0.05; **p < 0.01.
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(Figure 5A). Interestingly, even in the stimulated condition,
NAC treatment reduced the ratio of phospho-STAT1/total
STAT1 in NNS patient-derived MT-MLs (Figure 5B). To
elucidate the source of the ROS production, we next
measured the production of mitochondrial ROS by using
MitoSOX. Mitochondrial ROS was consistently increased
in MT-MLs (Figures 5C and 5D). On the other hand, a
NOX (NADPH oxidase) enzyme inhibitor, Apocynin, failed
to inhibit ROS production or the secretion of IL-6, MCP-1,
and IP-10 in all samples (Figures 5E–5G). Therefore, at least
in our iPSC-based system, the primary source of ROS in
MT-MLs seems to be mitochondria rather than NOX en-
zymes. This finding is consistent with a previous report
that concluded the elevated ROS upon proteasomal inhibi-
tion originated frommitochondria (Maharjan et al., 2014).
Consequently,MT-MLs in the untreated state exhibited a
‘‘primed’’ state that coincides with excessive ROS produc-
tion and with an inordinate amount of constitutively ex-
pressed STAT1. Engagement of the JAK/STAT and p38
MAPK pathways followed by IFN-g and TNF-a stimulation
in MT-MLs therefore elicited an augmented production of
inflammatory cytokines and chemokines, part of which is
mediated by the excessive production of ROS.
DISCUSSION
Recent advances in the field of proteasome diseases,
including NNS, have revealed a critical connection be-
tween the dysregulation of the immunoproteasome and
autoinflammation. However, the direct cause of the potent
inflammation has not been fully elucidated. We herein es-
tablished a panel of isogenic PSC clones by CRISPR/Cas9-
mediated genome editing the PSMB8 gene, which enabled
us to precisely evaluate the in vitro phenotypes of PSC-
derived differentiated progenies. We found that elevated
ROS levels in MT-MLs have a pivotal role in the proinflam-
matory response and can be ameliorated by antioxidant
therapy (Figure 6). Our PSC-basedmodels therefore provide
a possible alternative therapeutic option for NNS patients
andmay serve as a platform for seeking potential candidate
compounds for medical use.
PRAASs are usually characterized by a type I IFN response.
The primary source of type I IFN in CANDLE patients ap-
pears to be plasmacytoid dendritic cells (pDCs) (Brehm
et al., 2015), but it is unknown whether the production
of these cytokines is upregulated in the pDCs of NNS pa-
tients (Arima et al., 2011). Investigation should be given
to whether pDCs from NNS-patient-derived iPSCs produce
increased amounts of type I IFN, but currently there exists
no reliable differentiation method from hPSCs toward
pDCs. In the present study, we focused on the proinflam-
matory roles ofmonocytic cells inNNS rather than the pro-
duction of type I or type II IFNs. We established the in vitro
phenotypes of monocytic cells derived from PSCs and
confirmed that these cells produce significant amounts of
proinflammatory cytokines and chemokines under condi-
tions that induce the immunoproteasome, suggesting a
distinct role of these cells for maintaining the proinflam-
matory response in NNS.
Untreated MT-MLs showed lower chymotrypsin-like
enzymatic activity thanWT-MLs based on the constitutive
expression of b5i (Figures 1E–1G). This observation is in
line with previous findings that describe the constitutive
expression of immunoproteasome components in hemato-
poietic cells, including monocytes, macrophages, B cells,
and dendritic cells (Kimura et al., 2015; McCarthy and
Weinberg, 2015). In our PSC-derived model, MT-MLs
showed excessive production of ROS even in an untreated
state, probably because of the constitutive accumulation of
ubiquitinated proteins, which induced cellular stress (Fig-
ure 1H). Indeed, proteasome dysfunction is known to cause
mitochondrial damage and subsequent mitochondrial and
cellular ROS production (Maharjan et al., 2014). The exces-
sive production of superoxide species then activates MAPK
family molecules (Baas and Berk, 1995) and the JAK/STAT
cascade (Simon et al., 1998), thereby causing a proinflam-
matory response by upregulating downstream inflamma-
tory cytokines. Indeed, the enhanced phosphorylation of
STAT1 was observed in untreated MT-MLs (Figure 5A),
which is consistent with findings inNNS patient-derived fi-
broblasts, transformed B cells, and peripheral blood lym-
phocytes (Arima et al., 2011; Kitamura et al., 2011). Our
data support the hypothesis that the excessive production
of ROS is one of the direct downstream consequences of
abnormal immunoproteasome function, connecting
cellular stress to the activation of the proinflammatory
pathway.
Figure 4. PSMB8-Mutant PSC-MLs Show Enhanced ROS Production
(A and B) ROS production in untreated PSC-MLs or those stimulated with IFN-g with/without TNF-ameasured by CellROX. Flow diagram (A)
and quantification by mean fluorescence intensity (MFI) are shown (B).
(C and D) The amount of IL-6, MCP-1, and IP-10 secreted from PSC-MLs. Cells were pretreated for 3 hr with the indicated antioxidants and
subsequently treated with IFN-g and TNF-a for 20 hr.
(E and F) The amount of MCP-1 and IP-10 secreted from PSC-MLs. Cells were pretreated for 3 hr with the indicated antioxidants and
subsequently treated with IFN-g for 20 hr. IL-6 was not detected in this condition. Bars indicate the means ±SD (n = 3).
Asterisks indicate statistically significant differences by Student’s t test: *p < 0.05; **p < 0.01.
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In our model, ROS played a critical role in the excessive
productionofproinflammatory cytokines andchemokines,
because antioxidative treatment inactivated the produc-
tion of IL-6, MCP-1, and IP-10 through the p38 MAPK or
JAK/STAT pathways. However, whether these pathways
are necessary and sufficient for the pathogenesis of NNS re-
mains to be elucidated, as proteasome dysregulation also
causes other cellular stresses, such as endoplasmic reticu-
lum stress (Otoda et al., 2013). Since antioxidant treatment
did not reduce the accumulation of ubiquitinated proteins
(Maharjan et al., 2014), a therapeutic approach that leads to
the recovery of both cytokine overproduction and protea-
some dysfunction could be required. Since the modulation
of proteasome activity can be a promising therapeutic strat-
egy for a variety of diseases (HuangandChen, 2009) and the
dysfunction of chymotrypsin-like proteasome activity is
considered a primary cause of NNS (Kanazawa, 2012), we
also tried to enhance chymotrypsin-like proteasome activ-
ity with betulinic acid (BA). The application of BA led to
the recovery of the chymotrypsin-like activity in both
MT- andWT-MLs in adose-dependentmanner (Figure S6A).
However, the cytokine and chemokine production was not
reduced in BA-treated PSC-MLs (Figure S6B), possibly due to
BA off-target effects, such as activation of the p38 MAPK
pathway (Tan et al., 2003). Consistent with a previous
report (Trader et al., 2017), BA also failed to recover the
constitutive accumulation of ubiquitinated proteins in
MT-MLs (Figure S6C). These data indicate that, although
it couldupregulate chymotrypsin-likeproteolytic activities,
BA is insufficient for recovering the phenotypes associated
with the disease-associatedmutation. Therefore, further ef-
forts are required to identify compounds that are effective at
recovering immunoproteasome activities and resolving
ubiquitinated proteins. We believe that our PSC-ML-based
model can serve as a platform for high-throughput
screening forfinding these compounds, because this system
enables functional assays to investigate the production of
cytokines and the function of proteasomes in 96- or 384-
well plates using immortalized PSC-MLs.
Interestingly, a JAK inhibitor, P6, suppressed the secre-
tion of IL-6 and MCP-1, both of which are mainly depen-
dent on activation of the MAPK pathway (Figures 3B and
3D). On the other hand, a p38 MAPK inhibitor,
SB202190, reduced not only the secretion of IL-6 and
MCP-1, but also that of IP-10, which is mainly dependent
on activation of the JAK/STAT pathway (Figures 3C and
3E). IFN-dependent production of IP-10 was suppressed
by SB202190 even without TNF-a stimulation (Figure 3E).
A part of this crosstalk seemed to occur under the influ-
ence of increased ROS, because an antioxidant, NAC,
resolved the hyper-phosphorylation of STAT1 in unstimu-
lated MT-MLs. Although the enhancement of STAT-
dependent transcription by activation of the p38 MAPK
pathway has been reported (Ramsauer et al., 2002), ROS-
induced simultaneous activation of the p38 MAPK and
JAK/STAT pathways has not. ROS may be a second
messenger that enhances the p38 MAPK pathway, as
NAC reduced the downstream cytokine production
without affecting p38 MAPK phosphorylation (Figures
5A and 5B). Since the therapeutic use of p38 MAPK inhib-
itors or JAK inhibitors can be associated with severe side
effects, such as secondary immune deficiency (Blume-Pey-
tavi and Vogt, 2015; Sonbol et al., 2013), our results may
support the possible use of antioxidants as an alternative
therapeutic option for NNS and related immunoprotea-
some disorders (Figure 6).
Although progressive lipomuscular atrophy is an impor-
tant phenotype that affects the quality of life of NNS pa-
tients, findings related to the functional roles of immuno-
proteasomes in affected tissues are relatively limited.
Since PSCs can differentiate into other affected cells, such
asmyotubes and adipocytes, the tissue- or cell-type-specific
pathophysiology of NNS can be explored using these prog-
enies. The co-culturing of non-hematopoietic cells with
PSC-derived immune cells will provide an opportunity for
dissecting the cell-autonomous and non-cell-autonomous
pathological mechanisms in muscle and adipose tissues.
Our PSC-based methods can also be applicable to PRAAS.
The validation of candidate compounds with these
PSC-derived progenies is therefore an important step in
the development of therapeutic applications for immuno-
proteasome diseases.
Figure 5. Enhanced Production of Mitochondrial ROS and Activation of the JAK/STAT Pathway in MT-MLs
(A) Western blotting analysis of whole-cell lysates of PSC-ML lines probed for total and phosphorylated STAT1 (pY701) or total and
phosphorylated p38 MAPK (pT180/pY182). PSC-ML lines were pretreated with NAC for 3 hr and then with IFN-g for 1 hr.
(B) Densitometric quantification of western blot bands of only the IFN-g condition in (A). The NAC-treated group was measured by the fold
change in the phosphorylation of STAT1/total STAT1 relative to the corresponding untreated group.
(C and D) Mitochondrial ROS production in PSC-MLs untreated or treated with IFN-g with/without TNF-a measured by MitoSOX. Flow
diagram (C) and quantification by mean fluorescence intensity (MFI) (D) are shown.
(E and F) ROS production in PSC-MLs untreated or treated with IFN-g with/without TNF-a measured by CellROX in response to a NOX
inhibitor, apocynin. Flow diagram (E) and quantification by MFI (F) are shown.
(G) The amount of IL-6, MCP-1, and IP-10 secreted from PSC-MLs. Cells were pretreated 3 hr with apocynin and subsequently treated with
IFN-g and TNF-a for 20 hr. (D, F, and G) Bars indicate the means ±SD (n = 3).
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EXPERIMENTAL PROCEDURES
Please refer to the Supplemental Experimental Procedures for de-
tails of the methods.
Study Approval
This study was approved by the Ethics Committees of Kyoto Uni-
versity and Wakayama Medical University. Written informed con-
sent was obtained from the patients or their guardians in accor-
dance with the Declaration of Helsinki. The use of human ESCs
was approved by theMinistry of EducationCulture, Sports, Science
and Technology (MEXT) of Japan. The study plan for recombinant
DNA research has been approved by the recombinant DNA exper-
iments safety committee of Kyoto University.
Statistics
All statistical analyses were performed using Excel or R software
programs. ‘‘n’’ stands for the number of independent experimental
Figure 6. A Proposed Model of Autoinflammation Induced by PSMB8 with the NNS-Associated Mutation
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replications. The values are presented as the mean ± SD. Statistical
significance was evaluated using either Student’s t test or the Wil-
coxon rank-sum test.
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